Literature DB >> 16046005

STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating.

Rosa L Fradley1, Gillian F O'Meara, Richard J Newman, Annie Andrieux, Didier Job, David S Reynolds.   

Abstract

Schizophrenia is a chronic and debilitating disease which is thought to arise from a neuro-developmental disorder. Both the stable tubule-only polypeptide (STOP) protein and the N-methyl-D-aspartate (NMDA) NR1 subunit are involved in neuronal development and physiology. It has therefore been postulated that transgenic mice lacking either the STOP or the NMDAR1 gene would show a 'schizophrenic-like' phenotype. Here, STOP knockout and NMDA NR1 hypomorphic mice were assessed in a behavioural measure that can be used to detect schizophrenic-like phenotypes: a change in sensorimotor gating, measured through prepulse inhibition (PPI). STOP knockout mice were further assessed in another measure of 'schizophrenic-like behaviour': hyperlocomotion. The PPI deficit exhibited by both the STOP knockout and NMDA knockdown mice could not be reversed by acute treatment with the atyptical antipsychotic, clozapine (1 mg/kg, i.p.) but the hyperlocomotion shown by the STOP knockout mice was reversed with the same acute dose of clozapine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16046005     DOI: 10.1016/j.bbr.2005.05.012

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  51 in total

1.  Mice with reduced NMDA receptor expression: more consistent with autism than schizophrenia?

Authors:  M J Gandal; R L Anderson; E N Billingslea; G C Carlson; T P L Roberts; S J Siegel
Journal:  Genes Brain Behav       Date:  2012-08       Impact factor: 3.449

Review 2.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

3.  Nitric oxide synthase mediates the ability of darbepoetin alpha to improve the cognitive performance of STOP null mice.

Authors:  Kosuke Kajitani; Michael Thorne; Michel Samson; George S Robertson
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

4.  Environmental Enrichment Ameliorates Behavioral Impairments Modeling Schizophrenia in Mice Lacking Metabotropic Glutamate Receptor 5.

Authors:  Emma L Burrows; Caitlin E McOmish; Laetitia S Buret; Maarten Van den Buuse; Anthony J Hannan
Journal:  Neuropsychopharmacology       Date:  2015-02-10       Impact factor: 7.853

5.  Neural activation deficits in a mouse genetic model of NMDA receptor hypofunction in tests of social aggression and swim stress.

Authors:  Gary E Duncan; Ken Inada; Joseph S Farrington; Beverly H Koller; Sheryl S Moy
Journal:  Brain Res       Date:  2009-02-13       Impact factor: 3.252

6.  Repetitive behavior profile and supersensitivity to amphetamine in the C58/J mouse model of autism.

Authors:  Sheryl S Moy; Natallia V Riddick; Viktoriya D Nikolova; Brian L Teng; Kara L Agster; Randal J Nonneman; Nancy B Young; Lorinda K Baker; Jessica J Nadler; James W Bodfish
Journal:  Behav Brain Res       Date:  2013-11-08       Impact factor: 3.332

Review 7.  Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies.

Authors:  Rae Price; Bahar Salavati; Ariel Graff-Guerrero; Daniel M Blumberger; Benoit H Mulsant; Zafiris J Daskalakis; Tarek K Rajji
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-05-10       Impact factor: 5.067

8.  New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia.

Authors:  Avia Merenlender-Wagner; Zeev Shemer; Olga Touloumi; Roza Lagoudaki; Eliezer Giladi; Annie Andrieux; Nikolaos C Grigoriadis; Illana Gozes
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

Review 9.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

Review 10.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.